This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Karyn O'Neil, PhD
Chief Scientific Officer at Ar­o Biotherapeutics


Karyn O’Neil is the CSO, Arō Biotherapeutics. She was previously the Venture Leader for Centyrex, a J&J Venture focused on designer protein platform technologies. She is co-inventor of the Centyrin patents, and has led the team focused on advancing the Centyrin platform since its inception. Karyn’s team applied protein engineering, nucleic acid chemistry and chemical conjugation technologies to enable Centyrin – mediated intracellular delivery of nucleic acid cargos in a cell specific manner.  Karyn joined Centocor/J&J in 2001 where, prior to working on Centyrins, she held positions of increasing responsibility, ultimately becoming a Director of Antibody Therapeutics.  There she played a leadership role in the discovery & optimization of multiple clinical candidates.

Agenda Sessions

  • Centyrin-targeted siRNA Conjugates Demonstrate Potential New Therapeutic Approach for Reduction of Skeletal Muscle Glycogen in Pompe Disease